- BioMark Diagnostic Solutions, a subsidiary of BioMark Diagnostics Inc. (BUX), has announced that it will be opening a diagnostic laboratory in Québec City
- The laboratory will advance the clinical validation of BioMark’s proprietary liquid biopsy platform
- The clinical trials are supported by technology from Québec-based Phytronix Technologies
- BioMark Diagnostics is a Canadian oncology-focused company
- BioMark Diagnostics Inc. (BUX) is down 6.90 per cent and is currently trading at $0.54 per share
BioMark Diagnostic Solutions, a subsidiary of BioMark Diagnostics Inc. (BIX), has announced that it will be opening a diagnostic laboratory in Québec City.
The laboratory will primarily serve to advance the clinical validation of BioMark’s proprietary liquid biopsy platform for early lung cancer detection, monitoring and predicting response to treatment.
The company’s aim is to obtain regulatory approval and clinical laboratory licenses to be fully operational in early 2022.
Once operational, BioMark will initially begin offering its metabolomics biomarker panel for early lung cancer detection to physicians across the Province of Québec.
The opening of the new laboratory was prompted by BioMark’s technology alliance with Québec-based Phytronix Technologies.
The alliance has enhanced the company’s technical capabilities with automated sample preparation and mass spectrometry assay development, allowing BioMark to pursue further diagnostic research.
Phytronix will provide the optimized internal standards that are necessary for use in clinical settings, along with technical expertise required with high-throughput mass spectrometry.
Rashid Bux, CEO of BioMark, commented,
“This move to Québec City represents the successful accomplishment of our strategic plan to bring the company to its pre-commercialization stage.
“The fact that BioMark is spearheading the commercialization of its assay from its own clinical laboratory in Québec, Canada and later across North America will certainly create more value for our shareholders.”
The operation of the new diagnostic laboratory will be led by Dr. Jean-François (Jeff) Haince as general manager for BioMark Diagnostic Solutions.
BioMark Diagnostics is a Canadian oncology-focused company engaged in the development of the advanced-stage cancer diagnostic business.
BioMark Diagnostics Inc. (BUX) is down 6.90 per cent and is trading at $0.54 per share as of 10:46 am ET.
